Global Hodgkin’s Lymphoma Treatment Market Drivers and Regional Analysis
- Get link
- X
- Other Apps
Lymphoma is a malignancy that affects the body's lymphocytes, or white blood cells. There are two forms of lymphoma: Hodgkin's and Non- Hodgkin's. Classic Hodgkin's Lymphoma and nodular lymphocyte dominated Hodgkin's Lymphoma are the two types of Hodgkin's Lymphoma. Fever, abrupt weight loss, and swollen lymph nodes are some of the symptoms that indicate the presence of Hodgkin's Lymphoma in the body. Chemotherapy alone or in conjunction with radiotherapy is the most common treatment for Hodgkin's Lymphoma.
Global Hodgkin’s Lymphoma Treatment
Market Drivers
The global Hodgkin's
lymphoma market is predicted to develop as regulatory agencies approve
medications for the treatment of Hodgkin's lymphoma. In 2018, Health Canada
approved Seattle Genetics, Inc.'s supplementary New Drug Submission, which
increases the use of Adcetris (brentuximab vedotin) in combination with AVD
(adriamycin, vinblastine, and dacarbazine) chemotherapy in patients with
previously untreated Stage IV Hodgkin lymphoma (HL). Adcetris is used in
conjunction with doxorubicin, vinblastine, and dacarbazine to treat adult
patients with previously untreated Stage III or IV classical Hodgkin lymphoma
(cHL).
Hodgkin's Lymphoma Treatment Market
Global Hodgkin’s Lymphoma Treatment
Market Regional Analysis
Over the
projection period, North America is expected to maintain its dominance in the
worldwide Hodgkin's lymphoma market. The expansion of the North American
Hodgkin's lymphoma therapy market is predicted to be fueled by frequent
research and development activities conducted by the government and other
organisations. For example, in December 2016, the Ohio State University
Comprehensive Cancer Center and the National Cancer Institute (NCI) started a
U.S. FDA clinical trial of Ibrutinib in conjunction with Nivolumab in patients
with classical Hodgkin's Lymphoma in the United States to see how effective it
is. Ibritunib may inhibit cancer cell growth by inhibiting growth-related
enzymes, but Nivolumab may inhibit cancer cell growth by targeting distinct cells.
Clinical trials are currently in their second phase. The research will include
17 people and is expected to be completed by 2020.
- Get link
- X
- Other Apps
Comments
Post a Comment